Prevention of HSV‑2 Transmission in Discordant Couples

Daily Suppressive Antiviral Therapy

• Valacyclovir 500 mg taken orally once daily by the HSV‑2‑positive partner reduces overall acquisition risk for the uninfected partner by roughly 48–50 % (CDC MMWR Recommendations and Reports, 2009) 1.
• The same regimen lowers the incidence of symptomatic HSV‑2 disease in the susceptible partner by about 75 % (CDC MMWR Recommendations and Reports, 2009) 1.

Condom Use (Additive Protection)

• Consistent use of latex condoms cuts HSV‑2 transmission in half (≈ 50 % reduction) for both male‑to‑female and female‑to‑male exposures (CDC MMWR Recommendations and Reports, 2009) 1.

Behavioral Modifications

• Refraining from sexual contact during visible lesions or prodromal symptoms (e.g., tingling, burning, itching) eliminates exposure to the period with the highest viral load (CDC MMWR Recommendations and Reports, 2009) 1.
• The majority of HSV‑2 transmissions occur during asymptomatic periods when viral shedding is not clinically apparent, so avoiding sex only during outbreaks is insufficient (CDC MMWR Recommendations and Reports, 2009) 1.

Partner Testing and Counseling

• The HSV‑2‑negative partner should receive type‑specific serologic testing before initiating sexual activity to confirm susceptibility (CDC MMWR Recommendations and Reports, 2009) 1.
• If the partner is already HSV‑2 seropositive, further transmission risk between the couple is essentially eliminated (CDC MMWR Recommendations and Reports, 2009) 1.
• Disclosure of infection status and serologic testing in discordant couples are linked to a measurable reduction in transmission risk (CDC MMWR Recommendations and Reports, 2009) 1.
• Education that asymptomatic viral shedding is the primary mechanism of HSV‑2 spread is essential for effective counseling (CDC MMWR Recommendations and Reports, 2009) 1.

HSV‑2 and HIV Co‑Risk

• HSV‑2 infection increases the risk of acquiring HIV by approximately threefold, underscoring the importance of prevention in populations at risk for HIV (Clinical Infectious Diseases, 2022) 2.

Implementation Algorithm (Key Steps)

Partner Management in Symptomatic Genital HSV‑2 Infection

Partner Testing & Counseling

• Offer type‑specific HSV‑2 serologic testing and comprehensive transmission counseling to sexual partners; treatment is not required unless the partner develops symptomatic lesions. 3
• Require HSV‑2‑seronegative partners to undergo type‑specific serologic testing before resuming sexual activity; disclosure and testing in discordant couples lowers transmission risk. 3
• Provide intensive prevention counseling to seronegative partners to reduce acquisition risk. 3

Antiviral Treatment Strategies for the Infected Partner

• Initiate first‑episode therapy with valacyclovir 1 g orally twice daily for 7–10 days. 4
• After the acute episode, prescribe daily suppressive therapy with valacyclovir 500 mg once daily; this reduces transmission to susceptible heterosexual partners by approximately 48–50 %. 4
• Daily suppressive therapy also lowers asymptomatic viral shedding from about 10.8 % of days to 2.9 % of days. 5

Transmission Prevention Measures

• Advise abstinence from all sexual contact during visible lesions or prodromal symptoms. 3
• Emphasize that HSV‑2 can be transmitted during asymptomatic periods due to viral shedding, even when no lesions are visible. 5
• Recommend consistent latex condom use, which cuts transmission risk by roughly 50 % for both male‑to‑female and female‑to‑male intercourse. 3
• Combine daily suppressive therapy with consistent condom use for additive protection, though neither method eliminates transmission entirely. 5

Partner Treatment Indications

• Treat a partner only if they develop symptomatic genital lesions confirmed by viral culture, HSV DNA PCR, or antigen detection. 3
• If a partner experiences a first‑episode outbreak, treat with valacyclovir 1 g orally twice daily for 7–10 days. 4

Special Populations

• Perform routine type‑specific HSV‑2 testing in HIV‑infected individuals; HSV‑2 infection increases HIV acquisition risk about threefold. 3
• Use higher antiviral doses in HIV‑infected patients. 3
• Advise women of childbearing age to inform obstetric providers of their HSV‑2 status during pregnancy to mitigate neonatal infection risk. 5

Common Pitfalls to Avoid

• Do not rely on episodic (acute‑episode) antiviral treatment to reduce transmission; only daily suppressive therapy has demonstrated efficacy. 5
• Do not assume that avoiding sex solely during visible outbreaks sufficiently prevents spread, as most transmissions occur during asymptomatic periods. 5
• Do not overlook oral‑genital transmission; many individuals with oral HSV are unaware of their infection. 5